Gemphire Therapeutics (GEMP) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Gemphire Therapeutics (NASDAQ:GEMP) released its earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.04, Fidelity Earnings reports.

Shares of GEMP stock opened at $1.27 on Friday. The company has a market cap of $20.11 million, a price-to-earnings ratio of -0.39 and a beta of 2.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.64 and a current ratio of 4.64. Gemphire Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $11.43.

A number of research analysts have weighed in on the stock. Jefferies Financial Group cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Monday, August 13th. Zacks Investment Research cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Roth Capital lifted their price target on shares of Gemphire Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 27th. ValuEngine raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Raymond James cut shares of Gemphire Therapeutics from an “outperform” rating to a “market perform” rating and set a $22.00 price target on the stock. in a research report on Tuesday, August 7th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $17.13.

TRADEMARK VIOLATION WARNING: “Gemphire Therapeutics (GEMP) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2018/11/10/gemphire-therapeutics-gemp-releases-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Recommended Story: Leveraged Buyout (LBO) Explained

Earnings History for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply